Condition
Treatment Resistant Depressive Disorder
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Completed3
Unknown1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT01998958Phase 2CompletedPrimary
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
NCT05196971Phase 1CompletedPrimary
A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression
NCT02556606Phase 3CompletedPrimary
Ketamine for Treatment Resistant Late-Life Depression
NCT03667872Not ApplicableUnknownPrimary
Efficacy and Safety of DBS in Patients With Treatment-Resistant Depression
NCT02238730Not ApplicableWithdrawn
Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy
Showing all 5 trials